Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses

Rhea-AI Summary

Frontage Laboratories, Inc. (FRL) has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l, a premier Contract Research Organization in Italy, marking a significant achievement in establishing a base of operations in continental Europe. The acquisition is intended to benefit both existing Frontage and Accelera clients by leveraging Frontage's global platform and presents opportunities for further expansion in Europe.

EXTON, Pa., Jan. 2, 2024 /PRNewswire/ -- Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).

Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery & preclinical studies and clinical bioanalysis to pharma and biotechnology companies, academic institutions, and other healthcare stakeholders.

"Today marks a very significant achievement in the 23-year history of Frontage Laboratories, as we establish a base of operations in continental Europe. Accelera has developed a tremendous reputation for high quality R&D services and we look forward to welcoming their Bioanalytical and Drug Metabolism & Pharmacokinetics teams to the Frontage family," said Dr. Abdul Mutlib, CEO of Frontage. "We envision this strategic acquisition as a first step in establishing Frontage's footprint in Europe, with the intent of adding other service areas in the continent. We believe both existing Frontage and Accelera clients stand to benefit greatly by leveraging Frontage's increasingly global platform. In addition, we are looking forward to partnering with the remaining Accelera business on exciting opportunities to service clients across our organizations."

According to Dr. Song Li, Founder and Chairman of Frontage: "It has been a long-standing goal of Frontage to expand our operations in Europe. We consider ourselves fortunate to capitalize on our outstanding relationship with the Accelera team, which has enabled us to bring our plans to fruition. We are very enthusiastic about working together as we further develop the Frontage platform in Europe, starting from a footprint in the Biopark in Nerviano Lombardy, where Accelera and Nerviano Medical Sciences Srl have already established a long-standing and efficient value chain. As always, our ongoing focus will remain on delivering the highest levels of quality, technology and expertise to our clients."

"We are thrilled to join forces with Frontage as part of this strategic acquisition that marks a significant milestone in Accelera's journey," said Luca Leone, CEO of Accelera. "Accelera has built a strong reputation for delivering high-quality R&D services through all phases of drug research and development with extensive experience in oncology. This unique occasion opens up new horizons for collaboration and growth. On one hand, we will further focus on offering top-notch In-vivo (end-to-end services) for multiple emerging modalities. At the same time, we look forward to exploring exciting opportunities to serve our clients across continents through our ongoing collaboration. This partnership reflects our commitment to advancing research and providing innovative solutions in the European market and beyond," said Luca Leone, CEO of Accelera S.r.l.

"Having Frontage as part of the growing partners operating from our Biopark is a landmark moment for us. In addition to the endless potential of the Accelera-Frontage collaboration, Nerviano Medical Sciences can leverage Frontage's world-class capabilities to drive breakthrough advancements in our drug discovery and development process. By uniting our strengths, we believe we can accelerate the pace of innovation and make a lasting difference in the field where all companies of this strong alliance operate and thrive here in Nerviano," said Hugues Dolgos, CEO of NMS Group S.p.A and Nerviano Medical Sciences Srl.

About Frontage (www.frontagelab.com)

Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) which provides integrated, science-driven, product development services from drug discovery to late phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details visit: www.frontagelab.com

About NMS Group (https://www.nmsgroup.it/

NMS Group is the largest oncological R&D company in Italy with more than 400 employees, of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, which is a targeted kinase inhibitor used to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evidence of the competitiveness of the drug discovery platform of NMS Group. NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development.

The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

About Accelera (https://www.accelera.org/ )

Accelera is a premium tier Contract Research Organization (CRO), developing and offering new technologies and integrated programs to pharmaceutical and biotechnology companies around the world to move forward their innovative drug candidates up to registration

Major services available at Accelera include:

• IND/CTA enabling packages, including GLP general toxicology, safety pharmacology and genotoxicity;
• Toxicology studies in rodent and non-rodent species
• Preclinical development consultancy and preparation of regulatory documentation.

Accelera facilities are fully GLP and AAALAC accredited. Additional info available at: https://www.accelera.org.

Media Contact:
Debra Santolini, (908) 872-8092, dsantolini@frontagelab.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/frontage-laboratories-acquires-accelera-srls-bioanalytical-and-dmpk-businesses-302024885.html

SOURCE Frontage Laboratories, Inc.

FAQ

What did Frontage Laboratories, Inc. (FRL) announce on January 2, 2024?

Frontage Laboratories, Inc. (FRL) announced the completion of the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l.

Where is Accelera S.r.l. located?

Accelera S.r.l. is located in Nerviano, within the Lombardy region of Italy.

Who is the CEO of Frontage Laboratories, Inc. (FRL)?

Dr. Abdul Mutlib is the CEO of Frontage Laboratories, Inc. (FRL).

What is the significance of the acquisition for Frontage Laboratories, Inc. (FRL)?

The acquisition marks a significant achievement in establishing a base of operations in continental Europe for Frontage Laboratories, Inc. (FRL).

What are the future plans for Frontage Laboratories, Inc. (FRL) after the acquisition?

Frontage Laboratories, Inc. (FRL) plans to expand its operations in Europe and leverage its global platform to benefit both existing Frontage and Accelera clients.